Program
GNC-077
A development code.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Breast Neoplasms · Digestive System Neoplasms, led by Sichuan Biokin Pharmaceutical.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sichuan Biokin Pharmaceutical | 33 open or running | phase 1since Sep 20, 2024 | Sep 20, 2024 | Jun 2027phase 1 · NCT06755242 |
Also a collaborator on its studies: baili-bio-chengdu-pharmaceutical-co-ltd.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 20, 2024First studies: 2 phase 1 studiesFirst studyNCT06609187, NCT06612840
- Dec 25, 2024Phase 1 study in Digestive System NeoplasmsNCT06755242 · 20 planned · China
Ahead
- Jun 2027Primary completion: phase 1 study in Digestive System NeoplasmsNCT06755242
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06755242Digestive System Neoplasms · China | 1 | Not yet recruiting | Jun 2027 | 20 |
| NCT06612840Carcinoma, Non-Small-Cell Lung · China | 1 | Recruiting | Oct 2026 | 20 |
| NCT06609187Breast Neoplasms · China | 1 | Recruiting | Oct 2026 | 20 |
How it is read
Names in the registry
- “GNC-077”, 3 entries
Codes read as this program: GNC077.
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 1 study
- Breast Neoplasms, 1 study
- Digestive System Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.